193 related articles for article (PubMed ID: 33028151)
1. Candidate circulating microRNAs as potential diagnostic and predictive biomarkers for the monitoring of locally advanced breast cancer patients.
Ibrahim AM; Said MM; Hilal AM; Medhat AM; Abd Elsalam IM
Tumour Biol; 2020 Oct; 42(10):1010428320963811. PubMed ID: 33028151
[TBL] [Abstract][Full Text] [Related]
2. Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients.
Khalighfard S; Alizadeh AM; Irani S; Omranipour R
Sci Rep; 2018 Dec; 8(1):17981. PubMed ID: 30568292
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer.
Zhu W; Liu M; Fan Y; Ma F; Xu N; Xu B
Cancer Med; 2018 Sep; 7(9):4420-4433. PubMed ID: 30099860
[TBL] [Abstract][Full Text] [Related]
4. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
Raychaudhuri M; Bronger H; Buchner T; Kiechle M; Weichert W; Avril S
Breast Cancer Res Treat; 2017 Apr; 162(3):511-521. PubMed ID: 28181130
[TBL] [Abstract][Full Text] [Related]
5. Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment.
Al-Khanbashi M; Caramuta S; Alajmi AM; Al-Haddabi I; Al-Riyami M; Lui WO; Al-Moundhri MS
PLoS One; 2016; 11(4):e0152032. PubMed ID: 27064979
[TBL] [Abstract][Full Text] [Related]
6. Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients.
Kassem NM; Makar WS; Kassem HA; Talima S; Tarek M; Hesham H; El-Desouky MA
Asian Pac J Cancer Prev; 2019 Sep; 20(9):2749-2755. PubMed ID: 31554373
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
[TBL] [Abstract][Full Text] [Related]
8. Unravelling site-specific breast cancer metastasis: a microRNA expression profiling study.
Schrijver WA; van Diest PJ; ; Moelans CB
Oncotarget; 2017 Jan; 8(2):3111-3123. PubMed ID: 27902972
[TBL] [Abstract][Full Text] [Related]
9. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H
Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636
[TBL] [Abstract][Full Text] [Related]
10. Potential value of circulatory microRNA122 gene expression as a prognostic and metastatic prediction marker for breast cancer.
Saleh AA; Soliman SE; Habib MSE; Gohar SF; Abo-Zeid GS
Mol Biol Rep; 2019 Jun; 46(3):2809-2818. PubMed ID: 30835039
[TBL] [Abstract][Full Text] [Related]
11. Response Assessment With Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients With Locally Advanced Breast Cancer During Neoadjuvant Chemotherapy.
Akkiprik M; Koca S; Uğurlu MÜ; Ekren R; Peker Eyüboğlu İ; Alan Ö; Erzik C; Güllü Amuran G; Telli TA; Güllüoğlu MB; Sezerman U; Yumuk PF
Clin Breast Cancer; 2020 Aug; 20(4):332-343.e3. PubMed ID: 32201164
[TBL] [Abstract][Full Text] [Related]
12. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-9 as potential biomarker for breast cancer local recurrence and tumor estrogen receptor status.
Zhou X; Marian C; Makambi KH; Kosti O; Kallakury BV; Loffredo CA; Zheng YL
PLoS One; 2012; 7(6):e39011. PubMed ID: 22723919
[TBL] [Abstract][Full Text] [Related]
14. Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer.
Ding Q; Wang Y; Zuo Z; Gong Y; Krishnamurthy S; Li CW; Lai YJ; Wei W; Wang J; Manyam GC; Diao L; Zhang X; Lin F; Symmans WF; Sun L; Liu CG; Liu X; Debeb BG; Ueno NT; Harano K; Alvarez RH; Wu Y; Cristofanilli M; Huo L
Hum Pathol; 2018 Jul; 77():121-129. PubMed ID: 29689244
[TBL] [Abstract][Full Text] [Related]
15. Clinical potential of miR-940 as a diagnostic and prognostic biomarker in breast cancer patients.
Liu W; Xu Y; Guan H; Meng H
Cancer Biomark; 2018; 22(3):487-493. PubMed ID: 29843213
[TBL] [Abstract][Full Text] [Related]
16. The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma.
Fritz HKM; Lindgren D; Ljungberg B; Axelson H; Dahlbäck B
Eur J Cancer; 2014 Jul; 50(10):1758-1765. PubMed ID: 24793999
[TBL] [Abstract][Full Text] [Related]
17. Association of circulating miR-21, -205, and -182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment.
Chekhun VF; Borikun TV; Bazas VМ; Andriiv AV; Klyusov OМ; Yalovenko TМ; Lukianova NY
Exp Oncol; 2020 Sep; 42(3):162-166. PubMed ID: 32996748
[TBL] [Abstract][Full Text] [Related]
18. Decreased expression of microRNA-124 is an independent unfavorable prognostic factor for patients with breast cancer.
Dong LL; Chen LM; Wang WM; Zhang LM
Diagn Pathol; 2015 Apr; 10():45. PubMed ID: 25924779
[TBL] [Abstract][Full Text] [Related]
19. Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer.
Liu B; Su F; Chen M; Li Y; Qi X; Xiao J; Li X; Liu X; Liang W; Zhang Y; Zhang J
Hum Pathol; 2017 Jun; 64():44-52. PubMed ID: 28412211
[TBL] [Abstract][Full Text] [Related]
20. Dynamic Changes of Circulating Mir-155 Expression and the Potential Application as a Non-Invasive Biomarker in Breast Cancer.
Anwar SL; Tanjung DS; Fitria MS; Kartika AI; Sari DNI; Rakhmina D; Wardana T; Astuti I; Haryana SM; Aryandono T
Asian Pac J Cancer Prev; 2020 Feb; 21(2):491-497. PubMed ID: 32102529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]